Global Monoclonal Antibodies Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Monoclonal Antibodies Market is presumed to reach the market size of nearly USD 608.88 Billion by 2032 from USD 238.61 Billion in 2023 with a CAGR of 10.97% under the study period 2024-2032.

Monoclonal antibodies are identical immunoglobulins, generated from a single B-cell clone. It is an old immunological tool with applications in the fields of biochemistry, immunology, biotechnology, and applied biology. These are produced by the body's immune system in response to antigens such as bacteria, fungi, parasites, viruses, chemicals, and other substances. Scientists produce antibodies in the lab to mimic the action of the immune system to treat diseases with the help of immunotherapy. Monoclonal antibodies are generally administered by injection.

MARKET DYNAMICS

Production of monoclonal antibodies is an old practice in laboratory research. It is widely applied in the field of clinical medicine. Research from the laboratory globally is revealing additional applications in diverse branches of sciences. Growing search for new therapeutics is propelling the growth of the market. The continued interest in antibody product development is driven by the rapid advancement and understanding of disease at a molecular level. MAbs are extremely valuable for understanding basic immunological and molecular research due to their high specificity. MAbs are increasingly used for applications such as research and diagnosis, therapeutic tools in cancer and immunological disorders, and pharmacy, thus generating a great demand in the industry. Currently, MAbs account for one-third of all the new treatments for leukaemia, arthritis, breast cancer, and transplant, their role in disease prediction and detection offers promise. Scientist all over the world is looking for COVID-19 treatment. Ongoing research says that monoclonal antibodies could treat or even prevent COVID-19 and could promise as the next big thing for market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Monoclonal Antibodies. The growth and trends of Monoclonal Antibodies industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Monoclonal Antibodies market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Source Type

Murine
Chimeric
Humanized
Human

By Production Type

In Vivo
In Vitro

By Application

Oncology
Autoimmune Diseases
Infectious Diseases
Neurological Diseases
Others

By End-use

Hospitals
Specialty Centers
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Monoclonal Antibodies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Monoclonal Antibodies market include Novartis AG, Pfizer Inc, GlaxoSmithKline Plc, Amgen Inc., Merck & Co. Inc., Daiichi Sankyo Company, Limited, Abbott Laboratories, AstraZeneca Plc, Eli Lilly And Company, Johnson & Johnson Services Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11212693

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. MONOCLONAL ANTIBODIES - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Source Type
- 3.7.2 Market Attractiveness Analysis By Production Type
- 3.7.3 Market Attractiveness Analysis By Application
- 3.7.4 Market Attractiveness Analysis By End-use
- 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL MONOCLONAL ANTIBODIES MARKET ANALYSIS BY SOURCE TYPE

5.1. Overview By Source Type
5.2. Historical and Forecast Data
5.3. Analysis By Source Type
5.4. Murine Historic and Forecast Sales By Regions
5.5. Chimeric Historic and Forecast Sales By Regions
5.6. Humanized Historic and Forecast Sales By Regions
5.7. Human Historic and Forecast Sales By Regions

6. GLOBAL MONOCLONAL ANTIBODIES MARKET ANALYSIS BY PRODUCTION TYPE

6.1. Overview By Production Type
6.2. Historical and Forecast Data
6.3. Analysis By Production Type
6.4. In Vivo Historic and Forecast Sales By Regions
6.5. In Vitro Historic and Forecast Sales By Regions

7. GLOBAL MONOCLONAL ANTIBODIES MARKET ANALYSIS BY APPLICATION

7.1. Overview By Application
7.2. Historical and Forecast Data
7.3. Analysis By Application
7.4. Oncology Historic and Forecast Sales By Regions
7.5. Autoimmune Diseases Historic and Forecast Sales By Regions
7.6. Infectious Diseases Historic and Forecast Sales By Regions
7.7. Neurological Diseases Historic and Forecast Sales By Regions
7.8. Others Historic and Forecast Sales By Regions

8. GLOBAL MONOCLONAL ANTIBODIES MARKET ANALYSIS BY END-USE

8.1. Overview By End-use
8.2. Historical and Forecast Data
8.3. Analysis By End-use
8.4. Hospitals Historic and Forecast Sales By Regions
8.5. Specialty Centers Historic and Forecast Sales By Regions
8.6. Others Historic and Forecast Sales By Regions

9. GLOBAL MONOCLONAL ANTIBODIES MARKET ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
- 9.3.1 Overview, Historic and Forecast Data Sales Analysis
- 9.3.2 North America By Segment Sales Analysis
- 9.3.3 North America By Country Sales Analysis
- 9.3.4 United States Sales Analysis
- 9.3.5 Canada Sales Analysis
- 9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1 Overview, Historic and Forecast Data Sales Analysis
- 9.4.2 Europe By Segment Sales Analysis
- 9.4.3 Europe By Country Sales Analysis
- 9.4.4 United Kingdom Sales Analysis
- 9.4.5 France Sales Analysis
- 9.4.6 Germany Sales Analysis
- 9.4.7 Italy Sales Analysis
- 9.4.8 Russia Sales Analysis
- 9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1 Overview, Historic and Forecast Data Sales Analysis
- 9.5.2 Asia Pacific By Segment Sales Analysis
- 9.5.3 Asia Pacific By Country Sales Analysis
- 9.5.4 China Sales Analysis
- 9.5.5 India Sales Analysis
- 9.5.6 Japan Sales Analysis
- 9.5.7 South Korea Sales Analysis
- 9.5.8 Australia Sales Analysis
- 9.5.9 South East Asia Sales Analysis
- 9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1 Overview, Historic and Forecast Data Sales Analysis
- 9.6.2 Latin America By Segment Sales Analysis
- 9.6.3 Latin America By Country Sales Analysis
- 9.6.4 Brazil Sales Analysis
- 9.6.5 Argentina Sales Analysis
- 9.6.6 Peru Sales Analysis
- 9.6.7 Chile Sales Analysis
- 9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1 Overview, Historic and Forecast Data Sales Analysis
- 9.7.2 Middle East & Africa By Segment Sales Analysis
- 9.7.3 Middle East & Africa By Country Sales Analysis
- 9.7.4 Saudi Arabia Sales Analysis
- 9.7.5 UAE Sales Analysis
- 9.7.6 Israel Sales Analysis
- 9.7.7 South Africa Sales Analysis
- 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE MONOCLONAL ANTIBODIES COMPANIES

10.1. Monoclonal Antibodies Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11. COMPANY PROFILES OF MONOCLONAL ANTIBODIES INDUSTRY

11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Novartis AG
- 11.3.1 Company Overview
- 11.3.2 Company Revenue
- 11.3.3 Products
- 11.3.4 Recent Developments
11.4. Pfizer Inc
- 11.4.1 Company Overview
- 11.4.2 Company Revenue
- 11.4.3 Products
- 11.4.4 Recent Developments
11.5. GlaxoSmithKline Plc
- 11.5.1 Company Overview
- 11.5.2 Company Revenue
- 11.5.3 Products
- 11.5.4 Recent Developments
11.6. Amgen Inc.
- 11.6.1 Company Overview
- 11.6.2 Company Revenue
- 11.6.3 Products
- 11.6.4 Recent Developments
11.7. Merck & Co. Inc.
- 11.7.1 Company Overview
- 11.7.2 Company Revenue
- 11.7.3 Products
- 11.7.4 Recent Developments
11.8. Daiichi Sankyo Company
- 11.8.1 Company Overview
- 11.8.2 Company Revenue
- 11.8.3 Products
- 11.8.4 Recent Developments
11.9. Limited
- 11.9.1 Company Overview
- 11.9.2 Company Revenue
- 11.9.3 Products
- 11.9.4 Recent Developments
11.10. Abbott Laboratories
- 11.10.1 Company Overview
- 11.10.2 Company Revenue
- 11.10.3 Products
- 11.10.4 Recent Developments
11.11. AstraZeneca Plc
- 11.11.1 Company Overview
- 11.11.2 Company Revenue
- 11.11.3 Products
- 11.11.4 Recent Developments
11.12. Eli Lilly And Company
- 11.12.1 Company Overview
- 11.12.2 Company Revenue
- 11.12.3 Products
- 11.12.4 Recent Developments
11.13. Johnson & Johnson Services Inc
- 11.13.1 Company Overview
- 11.13.2 Company Revenue
- 11.13.3 Products
- 11.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies